Welcome to our dedicated page for Entrada Therapeutics SEC filings (Ticker: TRDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Entrada Therapeutics, Inc. (Nasdaq: TRDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Entrada is a clinical-stage biopharmaceutical company developing RNA- and protein-based therapeutics using its Endosomal Escape Vehicle (EEV™) technology for neuromuscular, ocular and other diseases.
For TRDA, key filings include periodic reports and current reports on Form 8-K. Recent Form 8-K filings furnished by Entrada cover quarterly financial results and corporate updates, such as results for the quarters ended June 30, 2025 and September 30, 2025. These filings confirm that Entrada’s common stock is registered on The Nasdaq Global Market under the symbol TRDA and identify the company as an emerging growth company.
Through this page, users can review how Entrada reports on its financial condition, collaboration revenue, research and development expenses, and other operating metrics in documents that are incorporated by reference into its SEC record. While the detailed content of annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy statements is not reproduced here, this filings hub is the starting point for locating those documents on EDGAR.
Stock Titan enhances access to Entrada’s SEC filings by organizing them chronologically and highlighting document types that matter to investors, such as Forms 8-K, 10-K, 10-Q and, when applicable, insider transaction reports on Form 4. AI-driven tools can help summarize lengthy filings and clarify technical language, allowing readers to more quickly understand how Entrada describes its EEV platform, clinical programs and financial results in its official regulatory disclosures.
Entrada Therapeutics (TRDA) – Form 4 insider transaction summary
Director and 10% owner Dr. Kush Parmar, through two affiliated venture funds, reported open-market sales totaling 125,000 common shares between 27 June and 1 July 2025. The sales were executed at prices ranging from $6.81 to $7.12 per share, generating roughly $0.9-1.2 million in proceeds (exact proceeds depend on final settlement).
- 5AM Ventures V, L.P. sold 92,891 shares across three trades and now owns 3,183,131 shares.
- 5AM Opportunities I, L.P. sold 32,109 shares and now owns 1,100,248 shares.
- The combined position after the transactions is approximately 4.28 million shares, meaning only about 2.8 % of their prior stake was divested.
No derivative securities were involved, and Dr. Parmar continues to disclaim beneficial ownership beyond his pecuniary interest. While insider selling often raises caution among investors, the modest percentage sold and the remaining large holding suggest routine portfolio rebalancing rather than a wholesale exit.
Form 4 filings dated 07/01/2025 disclose that venture–backed funds affiliated with 5AM Venture Management, a 10 % beneficial owner of Entrada Therapeutics (TRDA), executed a three-day program of open-market sales. The entities involved were 5AM Ventures V, L.P. (direct holder) and 5AM Opportunities I, L.P. (indirect holder). The sales were made on 06/27, 06/30 and 07/01 at prices ranging from $6.81 – $7.12 per share.
- Shares sold by 5AM Ventures V: 92,891 shares (55,735 + 18,578 + 18,578) for proceeds of roughly $639k.
- Shares sold by 5AM Opportunities I: 32,109 shares (19,265 + 6,422 + 6,422) for proceeds of roughly $220k.
- Total shares sold: 125,000 shares, representing about 2.8 % of the combined 4.41 million-share position held prior to the first transaction.
After the transactions, 5AM Ventures V holds 3,183,131 shares directly, while 5AM Opportunities I holds 1,100,248 shares indirectly, leaving the 5AM group with an aggregate stake of approximately 4.28 million shares. All reporting persons—5AM Partners V, 5AM Opportunities I (GP), and managing members Dr. Scott M. Rocklage and Andrew J. Schwab—remain classified as 10 % owners. No derivative securities were reported.
The filing signals modest insider selling by a large shareholder following a minor upward move in TRDA’s share price during the period. Although the group maintains a substantial ownership position, the reduction could be interpreted by investors as a slight negative sentiment shift or portfolio rebalancing.
Entrada Therapeutics, Inc. (TRDA) – Form 144 filing
An affiliate has filed a Form 144 to sell up to 19,265 common shares through TD Securities (USA) LLC on or after 27 June 2025. The proposed transaction carries an aggregate market value of $133,121.15. The shares were originally acquired on 28 September 2017 via a cash venture investment. With 37,953,417 shares outstanding, the maximum sale equals roughly 0.05 % of the issuer’s float, indicating minimal dilution or price pressure.
No other sales have been reported in the past three months, and the filer states they possess no undisclosed material adverse information. Form 144 is a notice only; it does not obligate the seller to complete the trade and provides no operating or earnings data. Given the small size of the stake, the market impact is expected to be immaterial, though investors often interpret insider intentions to sell as a mildly negative sentiment indicator.